Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent achievement in the clinical immunotherapy of hematological malignant tumors, leading to a rapid development of cellular immunotherapy in cancer treatment. Scientists are also aware of the prospective advantages of CAR ...
The development of NK cells primarily occurs from common lymphoid progenitors (CLPs) in the bone marrow, progressing through distinct stages, mainly including NK precursors (NKP), immature NK cells, and mature NK cells as illustrated in Fig.1. In the course of normal hematopoiesis, one of the ...
NK cells are able to recognize and kill “stressed cells” including cells infected with viruses, allogeneic cells, and tumor cells without prior sensitization in a non-HLA (human leukocyte antigen)-restricted manner. The effector functions in NK cells are regulated through a balance of signals de...
CAR-NK的细胞来源主要有三种:外周血、NK细胞系和具有分化潜能的干细胞。主要来源是外周血,在过去十年里,已经有较为有效的方法从外周血和外周血干细胞中纯化扩增足够量的NK细胞用于免疫治疗,并且逐步用于CAR修饰的研发中。自体NK细胞和异体NK细胞都可以进行CAR修饰,但是细胞特性不相同。异体NK细胞供者血液中存在着以T...
Ex vivoexpanded/activatedNK cellsderived from patients or donors are an option for NK cell-based therapy in MM. • NK celllines andchimeric antigen receptor(CAR)-NK cells may provide an off-the-shelf source for NK cell-based therapy. ...
Chimeric antigen receptor(CAR) is a synthesized transmembrane protein,which redirects the modified cells through specific or associated antigen on tumor cells.CAR-modified T/NK cells,especially CAR-T cells,are a new tool of rapidly developing of adoptive immunotherapy of tumor in recent years,they ...
Chimeric antigen receptor (CAR)-expressing T cells have been demonstrated successfully in the clinic to treat B-lymphoid malignancies. However, the potential utility of antigen-specific CAR-engineered natural-killer (NK) cells to treat MM has not been explored. In this study, we determined whether...
Chimeric antigen receptor T (CAR-T) cell therapy is a novel immunotherapy in which peripheral T cells are collected from a cancer patient, then a genetically engineered receptor specific to a tumor antigen is inserted to the collected T cells [1]. ...
CS1 is highly, and nearly ubiquitously, expressed on MM cells, while expression remains very low on NK cells, some T-cell subsets, and normal B cells, and also it is almost undetectable on myeloid cells. In addition, monoclonal antibody directed against CS1, elotuzumab, has already been ...
Chimeric antigen receptor (CAR)-expressing T cells have been demonstrated successfully in the clinic to treat B-lymphoid malignancies. However, the potential utility of antigen-specific CAR-engineered natural-killer (NK) cells to treat MM has not been explored. In this study, we determined whether...